Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Kristin Richards, Michael Johnsrud, Christopher Zacker & Rahul Sasané. (2024) Association Between Persistence with Oral Atypical Antipsychotic Medications and Hospital and Emergency Department Utilization in Medicaid Patients with Schizophrenia. Patient Preference and Adherence 18, pages 177-185.
Read now
Read now
Stefano Bramante, Gabriele Di Salvo, Giuseppe Maina & Gianluca Rosso. (2023) Paliperidone Palmitate: A Breakthrough Treatment for Schizophrenia? A Review on Patient Adherence Levels, Healthcare Resource Utilization and Costs. Neuropsychiatric Disease and Treatment 19, pages 519-530.
Read now
Read now
Anna Kotzeva, Deepali Mittal, Supriya Desai, Davneet Judge & Kunal Samanta. (2023) Socioeconomic burden of schizophrenia: a targeted literature review of types of costs and associated drivers across 10 countries. Journal of Medical Economics 26:1, pages 70-83.
Read now
Read now
S Kor Spoelstra, Jojanneke Bruins, Leonie Bais, Paul Seerden, Stynke Castelein & Henderikus Knegtering. (2022) One-Month versus Three-Month Formulation of Paliperidone Palmitate Treatment in Psychotic Disorders: Patients’, Relatives’, and Mental Health Professionals’ Perspectives. Patient Preference and Adherence 16, pages 615-624.
Read now
Read now
Antoine C El Khoury, Charmi Patel, Panagiotis Mavros, Ahong Huang, Li Wang & Richa Bashyal. (2021) Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia. Neuropsychiatric Disease and Treatment 17, pages 3159-3170.
Read now
Read now
Antoine El Khoury, Charmi Patel, Ahong Huang, Li Wang & Richa Bashyal. (2019) Transitioning from oral risperidone or paliperidone to once-monthly paliperidone palmitate: a real-world analysis among Veterans Health Administration patients with schizophrenia who have had at least one prior hospitalization. Current Medical Research and Opinion 35:12, pages 2159-2168.
Read now
Read now
Antoine C. El Khoury, Dominic Pilon, Laura Morrison, Nina Shak, Maude Vermette-Laforme, Tony B. Amos, Edward Kim & Patrick Lefebvre. (2019) The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia. Current Medical Research and Opinion 35:3, pages 395-405.
Read now
Read now
Robin Emsley & Sanja Kilian. (2018) Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review. Neuropsychiatric Disease and Treatment 14, pages 205-223.
Read now
Read now
Kruti Joshi, Marie-Hélène Lafeuille, Brianne Brown, Willy Wynant, Bruno Emond, Patrick Lefebvre & Neeta Tandon. (2017) Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting. Current Medical Research and Opinion 33:10, pages 1763-1772.
Read now
Read now
Articles from other publishers (17)
Ki Jin JeunKhalid M. KamalKeyuri AdhikariDavid A. NolfiMd. Najeeb AshrafChristopher Zacker. (2024) A systematic review of the real-world effectiveness and economic and humanistic outcomes of selected oral antipsychotics among patients with schizophrenia in the United States: Updating the evidence and gaps. Journal of Managed Care & Specialty Pharmacy 30:2, pages 183-199.
Crossref
Crossref
Christina J. Chen & Wanda Hilliard. (2023) Text Message Reminders for Long-Acting Injectable Antipsychotics in Patients with Schizophrenia Spectrum Disorders. Journal of the American Psychiatric Nurses Association.
Crossref
Crossref
Matthew C. Dickson, Michael M. Nguyen, Charmi Patel, Shannon C. Grabich, Carmela Benson, Terry Cothran & Grant H. Skrepnek. (2022) Adherence, Persistence, Readmissions, and Costs in Medicaid Members with Schizophrenia or Schizoaffective Disorder Initiating Paliperidone Palmitate Versus Switching Oral Antipsychotics: A Real-World Retrospective Investigation. Advances in Therapy 40:1, pages 349-366.
Crossref
Crossref
Xiuru Su, Long Zhao, Yujie Shang, Yingnan Chen, Xiaowen Liu, Xuan Wang, Meihong Xiu, Huijing Yu & Lijun Liu. (2022) Repetitive transcranial magnetic stimulation for psychiatric symptoms in long-term hospitalized veterans with schizophrenia: A randomized double-blind controlled trial. Frontiers in Psychiatry 13.
Crossref
Crossref
Amber Martin, Leona Bessonova, Rachel Hughes, Michael J. Doane, Amy K. O’Sullivan, Kassandra Snook, Allie Cichewicz, Peter J. Weiden & Philip D. Harvey. (2022) Systematic Review of Real-World Treatment Patterns of Oral Antipsychotics and Associated Economic Burden in Patients with Schizophrenia in the United States. Advances in Therapy 39:9, pages 3933-3956.
Crossref
Crossref
Chizimuzo T.C. Okoli, Amani Kappi, Tianyi Wang, Andrew Makowski & Andrew T. Cooley. (2021) The effect of long‐acting injectable antipsychotic medications compared with oral antipsychotic medications among people with schizophrenia: A systematic review and meta‐analysis. International Journal of Mental Health Nursing 31:3, pages 469-535.
Crossref
Crossref
Cristiana Montemagni, Elisa Del Favero, Elena Cocuzza, Flavio Vischia & Paola Rocca. (2022) Effect of long-acting injectable antipsychotics on hospitalizations and global functioning in schizophrenia: a naturalistic mirror-image study. Therapeutic Advances in Psychopharmacology 12, pages 204512532211225.
Crossref
Crossref
Lionel CailholÉric PelletierLouis RochetteSuzane RenaudMarion KochPierre DavidEvens VilleneuveCarlotta LunghiAlain Lesage. (2021) Utilization of Health Care Services by Patients With Cluster B Personality Disorders or Schizophrenia. Psychiatric Services 72:12, pages 1392-1399.
Crossref
Crossref
Taishiro Kishimoto, Katsuhiko Hagi, Shunya Kurokawa, John M Kane & Christoph U Correll. (2021) Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies. The Lancet Psychiatry 8:5, pages 387-404.
Crossref
Crossref
Dee Lin, Philippe Thompson-Leduc, Isabelle Ghelerter, Ha Nguyen, Marie-Hélène Lafeuille, Carmela Benson, Panagiotis Mavros & Patrick Lefebvre. (2021) Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis. CNS Drugs 35:5, pages 469-481.
Crossref
Crossref
Dasom Lee, Boung Chul Lee, Soo-Hee Choi, Do-Hyung Kang, Duk-In Jon & Myung Hun Jung. (2020) Effects of Paliperidone Palmitate on Healthcare Utilization and Costs for Patients with Schizophrenia: A Claim-based Mirror-image Study in South Korea. Clinical Psychopharmacology and Neuroscience 18:2, pages 303-310.
Crossref
Crossref
Antoine C. El KhouryDominic PilonLaura MorrisonNina Shak, Amanda LlanezaEdward KimPatrick Lefebvre. (2020) Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia. Journal of Managed Care & Specialty Pharmacy 26:2, pages 176-185.
Crossref
Crossref
Halise Devrimci-Ozguven, Murad Atmaca, Zeynep Baran, Cengiz Cengisiz, Cem Çinar, Atila Erol, Yasin Genç, Hasan Karadağ, Kamuran Karakülah, Umut Karasu, Mehmet Cemal Kaya, Emre Kizil, Halil Özcan, Ahmet Tiryaki, Alp Üçok, Cenk Varlik, Sila Menekşe Yazar & Mesut Yildiz. (2019) Efficacy and Safety of Paliperidone Palmitate Treatment in Patients With Schizophrenia. Journal of Clinical Psychopharmacology 39:6, pages 604-610.
Crossref
Crossref
Charmi Patel, Antoine El Khoury, Ahong Huang, Li Wang, Onur Baser & Kruti Joshi. (2019) Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis. Advances in Therapy 36:10, pages 2941-2953.
Crossref
Crossref
Bruno Emond, Kruti Joshi, Antoine C. El Khoury, Marie-Hélène Lafeuille, Dominic Pilon, Neeta Tandon, Hela Romdhani & Patrick Lefebvre. (2018) Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate. PharmacoEconomics - Open 3:2, pages 177-188.
Crossref
Crossref
Tingjian Yan, Mallik Greene, Eunice Chang, Michael S Broder, Maëlys Touya, Jennifer Munday & Ann Hartry. (2019) Hospitalization risk factors in antipsychotic-treated schizophrenia, bipolar I disorder or major depressive disorder. Journal of Comparative Effectiveness Research 8:4, pages 217-227.
Crossref
Crossref
Yi-Ju Pan, Kuei-Hong Kuo & Ling-Ling Yeh. (2019) Healthcare cost, service use and mortality in major psychiatric disorders in Taiwan. Journal of Affective Disorders 246, pages 112-120.
Crossref
Crossref